Glenmark Pharmaceuticals Inc., USA announced the launch of Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), a bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan Ophthalmic Solution, 0.005% of Upjohn US 2 LLC, the company said in a press release.

Commenting on the launch, Marc Kikuchi, president and business head, North America said: “We are excited to announce the launch of our fourth ophthalmic product, Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), growing our portfolio of products within the ophthalmic channel. This addition highlights our commitment to meeting market needs and providing quality solutions for our customers.”